Enhertu improves both progression-free and overall survival in Destiny-Breast04 trial in patients… EP News Bureau Feb 22, 2022 First HER2-low metastatic breast cancer phase-III results for AstraZeneca and Daiichi Sankyo’s Enhertu offer potential to redefine…
